CSF2 and Sepsis: Based on a Cochrane meta-analysis [82], which showed no benefit of GM-CSF in newborns and infants who were not selected based on the presence of neutropenia, the need for personalized treatment approaches when using immune-stimulatory therapies in sepsis has been highlighted [82].